APO Research
Talk to an analyst

APO RESEARCH · REPORT

Urate-stimulating Excretion Agents

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Urate-stimulating Excretion Agents Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

27 December 2025186 pages

Choose your research edition.

Industry ResearchUrate-stimulating Excretion Agents Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Urate-stimulating Excretion Agents Industry Growth and Trends Forecast to 203298 pages · $3,450 USDMarket StructureGlobal Urate-stimulating Excretion Agents Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032186 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Urate-stimulating Excretion Agents Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Urate-stimulating Excretion Agents Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Urate-stimulating Excretion Agents market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Urate-stimulating Excretion Agents is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Urate-stimulating Excretion Agents is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Urate-stimulating Excretion Agents is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Urate-stimulating Excretion Agents is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Urate-stimulating Excretion Agents include Eisai, Teva, Towa Pharmaceutical, Lannett Company, Fuji Yakuhin, Excella and AstraZeneca, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Urate-stimulating Excretion Agents market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Urate-stimulating Excretion Agents and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Urate-stimulating Excretion Agents sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Urate-stimulating Excretion Agents market size, projected growth trends, production technologies, key applications, and end-use industries.

Urate-stimulating Excretion Agents Segment by Company

Eisai

Teva

Towa Pharmaceutical

Lannett Company

Fuji Yakuhin

Excella

AstraZeneca

Urate-stimulating Excretion Agents Segment by Type

Benzbromarone

Probenecid

Dotinurad

Lesinurad

Other

Urate-stimulating Excretion Agents Segment by Application

Retail Pharmacies

Hospitals and Clinics

Other

Urate-stimulating Excretion Agents Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Urate-stimulating Excretion Agents market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Urate-stimulating Excretion Agents and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Urate-stimulating Excretion Agents.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Urate-stimulating Excretion Agents market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Urate-stimulating Excretion Agents manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Urate-stimulating Excretion Agents in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Urate-stimulating Excretion Agents in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Urate-stimulating Excretion Agents Industry Trends Table 2. Urate-stimulating Excretion Agents Industry Drivers Table 3. Urate-stimulating Excretion Agents Industry Opportunities and Challenges Table 4. Urate-stimulating Excretion Agents Industry Restraints Table 5. Global Urate-stimulating Excretion Agents Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Urate-stimulating Excretion Agents Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Urate-stimulating Excretion Agents Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Urate-stimulating Excretion Agents Sales Market Share by Manufacturers Table 9. Global Urate-stimulating Excretion Agents Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Urate-stimulating Excretion Agents Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Urate-stimulating Excretion Agents Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Urate-stimulating Excretion Agents Manufacturers, Product Type & Application Table 13. Global Urate-stimulating Excretion Agents Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Urate-stimulating Excretion Agents by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Benzbromarone Table 17. Major Manufacturers of Probenecid Table 18. Major Manufacturers of Dotinurad Table 19. Major Manufacturers of Lesinurad Table 20. Major Manufacturers of Other Table 21. Global Urate-stimulating Excretion Agents Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 22. Global Urate-stimulating Excretion Agents Sales by Type (2021-2026) & (K Units) Table 23. Global Urate-stimulating Excretion Agents Sales by Type (2027-2032) & (K Units) Table 24. Global Urate-stimulating Excretion Agents Sales Market Share by Type (2021-2026) Table 25. Global Urate-stimulating Excretion Agents Sales Market Share by Type (2027-2032) Table 26. Global Urate-stimulating Excretion Agents Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 27. Global Urate-stimulating Excretion Agents Revenue by Type (2021-2026) & (K Units) Table 28. Global Urate-stimulating Excretion Agents Revenue by Type (2027-2032) & (K Units) Table 29. Global Urate-stimulating Excretion Agents Revenue Market Share by Type (2021-2026) Table 30. Global Urate-stimulating Excretion Agents Revenue Market Share by Type (2027-2032) Table 31. Major Manufacturers of Retail Pharmacies Table 32. Major Manufacturers of Hospitals and Clinics Table 33. Major Manufacturers of Other Table 34. Global Urate-stimulating Excretion Agents Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 35. Global Urate-stimulating Excretion Agents Sales by Application (2021-2026) & (K Units) Table 36. Global Urate-stimulating Excretion Agents Sales by Application (2027-2032) & (K Units) Table 37. Global Urate-stimulating Excretion Agents Sales Market Share by Application (2021-2026) Table 38. Global Urate-stimulating Excretion Agents Sales Market Share by Application (2027-2032) Table 39. Global Urate-stimulating Excretion Agents Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 40. Global Urate-stimulating Excretion Agents Revenue by Application (2021-2026) & (K Units) Table 41. Global Urate-stimulating Excretion Agents Revenue by Application (2027-2032) & (K Units) Table 42. Global Urate-stimulating Excretion Agents Revenue Market Share by Application (2021-2026) Table 43. Global Urate-stimulating Excretion Agents Revenue Market Share by Application (2027-2032) Table 44. Global Urate-stimulating Excretion Agents Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 45. Global Urate-stimulating Excretion Agents Sales by Region (2021-2026) & (K Units) Table 46. Global Urate-stimulating Excretion Agents Sales Market Share by Region (2021-2026) Table 47. Global Urate-stimulating Excretion Agents Sales Forecasted by Region (2027-2032) & (K Units) Table 48. Global Urate-stimulating Excretion Agents Sales Forecasted Market Share by Region (2027-2032) Table 49. North America Urate-stimulating Excretion Agents Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 50. North America Urate-stimulating Excretion Agents Sales by Country (2021-2026) & (K Units) Table 51. North America Urate-stimulating Excretion Agents Sales by Country (2027-2032) & (K Units) Table 52. Europe Urate-stimulating Excretion Agents Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. Europe Urate-stimulating Excretion Agents Sales by Country (2021-2026) & (K Units) Table 54. Europe Urate-stimulating Excretion Agents Sales by Country (2027-2032) & (K Units) Table 55. Asia Pacific Urate-stimulating Excretion Agents Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Asia Pacific Urate-stimulating Excretion Agents Sales by Country (2021-2026) & (K Units) Table 57. Asia Pacific Urate-stimulating Excretion Agents Sales by Country (2027-2032) & (K Units) Table 58. South America, Middle East and Africa Urate-stimulating Excretion Agents Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 59. South America, Middle East and Africa Urate-stimulating Excretion Agents Sales by Country (2021-2026) & (K Units) Table 60. South America, Middle East and Africa Urate-stimulating Excretion Agents Sales by Country (2027-2032) & (K Units) Table 61. Global Urate-stimulating Excretion Agents Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 62. Global Urate-stimulating Excretion Agents Revenue by Region (2021-2026) & (US$ Million) Table 63. Global Urate-stimulating Excretion Agents Revenue by Region (2027-2032) & (US$ Million) Table 64. Global Urate-stimulating Excretion Agents Revenue Market Share by Region (2021-2026) Table 65. Global Urate-stimulating Excretion Agents Revenue Market Share by Region (2027-2032) Table 66. Eisai Company Information Table 67. Eisai Business Overview Table 68. Eisai Urate-stimulating Excretion Agents Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Eisai Urate-stimulating Excretion Agents Product Portfolio Table 70. Eisai Recent Development Table 71. Teva Company Information Table 72. Teva Business Overview Table 73. Teva Urate-stimulating Excretion Agents Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Teva Urate-stimulating Excretion Agents Product Portfolio Table 75. Teva Recent Development Table 76. Towa Pharmaceutical Company Information Table 77. Towa Pharmaceutical Business Overview Table 78. Towa Pharmaceutical Urate-stimulating Excretion Agents Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Towa Pharmaceutical Urate-stimulating Excretion Agents Product Portfolio Table 80. Towa Pharmaceutical Recent Development Table 81. Lannett Company Company Information Table 82. Lannett Company Business Overview Table 83. Lannett Company Urate-stimulating Excretion Agents Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Lannett Company Urate-stimulating Excretion Agents Product Portfolio Table 85. Lannett Company Recent Development Table 86. Fuji Yakuhin Company Information Table 87. Fuji Yakuhin Business Overview Table 88. Fuji Yakuhin Urate-stimulating Excretion Agents Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Fuji Yakuhin Urate-stimulating Excretion Agents Product Portfolio Table 90. Fuji Yakuhin Recent Development Table 91. Excella Company Information Table 92. Excella Business Overview Table 93. Excella Urate-stimulating Excretion Agents Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 94. Excella Urate-stimulating Excretion Agents Product Portfolio Table 95. Excella Recent Development Table 96. AstraZeneca Company Information Table 97. AstraZeneca Business Overview Table 98. AstraZeneca Urate-stimulating Excretion Agents Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 99. AstraZeneca Urate-stimulating Excretion Agents Product Portfolio Table 100. AstraZeneca Recent Development Table 101. Key Raw Materials Table 102. Raw Materials Key Suppliers Table 103. Urate-stimulating Excretion Agents Distributors List Table 104. Urate-stimulating Excretion Agents Customers List Table 105. Research Programs/Design for This Report Table 106. Authors List of This Report Table 107. Secondary Sources Table 108. Primary Sources List of Figures Figure 1. Urate-stimulating Excretion Agents Product Image Figure 2. Global Urate-stimulating Excretion Agents Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Urate-stimulating Excretion Agents Market Size (2021-2032) & (US$ Million) Figure 4. Global Urate-stimulating Excretion Agents Sales (2021-2032) & (K Units) Figure 5. Global Urate-stimulating Excretion Agents Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Urate-stimulating Excretion Agents Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Benzbromarone Image Figure 9. Probenecid Image Figure 10. Dotinurad Image Figure 11. Lesinurad Image Figure 12. Other Image Figure 13. Global Urate-stimulating Excretion Agents Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Urate-stimulating Excretion Agents Sales Market Share 2021 VS 2025 VS 2032 Figure 15. Global Urate-stimulating Excretion Agents Sales Market Share by Type (2021-2032) Figure 16. Global Urate-stimulating Excretion Agents Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 17. Global Urate-stimulating Excretion Agents Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Urate-stimulating Excretion Agents Revenue Market Share by Type (2021-2032) Figure 19. Retail Pharmacies Image Figure 20. Hospitals and Clinics Image Figure 21. Other Image Figure 22. Global Urate-stimulating Excretion Agents Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Urate-stimulating Excretion Agents Sales Market Share 2021 VS 2025 VS 2032 Figure 24. Global Urate-stimulating Excretion Agents Sales Market Share by Application (2021-2032) Figure 25. Global Urate-stimulating Excretion Agents Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 26. Global Urate-stimulating Excretion Agents Revenue Market Share 2021 VS 2025 VS 2032 Figure 27. Global Urate-stimulating Excretion Agents Revenue Market Share by Application (2021-2032) Figure 28. North America Urate-stimulating Excretion Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 29. North America Urate-stimulating Excretion Agents Sales Market Share by Country (2021-2032) Figure 30. U.S. Urate-stimulating Excretion Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Canada Urate-stimulating Excretion Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Mexico Urate-stimulating Excretion Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Europe Urate-stimulating Excretion Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Europe Urate-stimulating Excretion Agents Sales Market Share by Country (2021-2032) Figure 35. Germany Urate-stimulating Excretion Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 36. France Urate-stimulating Excretion Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 37. U.K. Urate-stimulating Excretion Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Italy Urate-stimulating Excretion Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Netherlands Urate-stimulating Excretion Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Asia Pacific Urate-stimulating Excretion Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Asia Pacific Urate-stimulating Excretion Agents Sales Market Share by Country (2021-2032) Figure 42. China Urate-stimulating Excretion Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Japan Urate-stimulating Excretion Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 44. South Korea Urate-stimulating Excretion Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Southeast Asia Urate-stimulating Excretion Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 46. India Urate-stimulating Excretion Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 47. Australia Urate-stimulating Excretion Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South America, Middle East and Africa Urate-stimulating Excretion Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South America, Middle East and Africa Urate-stimulating Excretion Agents Sales Market Share by Country (2021-2032) Figure 50. Brazil Urate-stimulating Excretion Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 51. South Africa Urate-stimulating Excretion Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Saudi Arabia Urate-stimulating Excretion Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Turkey Urate-stimulating Excretion Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Argentina Urate-stimulating Excretion Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 55. UAE Urate-stimulating Excretion Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Egypt Urate-stimulating Excretion Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Chile Urate-stimulating Excretion Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Global Urate-stimulating Excretion Agents Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 59. Global Urate-stimulating Excretion Agents Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 60. North America Urate-stimulating Excretion Agents Revenue (2021-2032) & (US$ Million) Figure 61. North America Urate-stimulating Excretion Agents Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Europe Urate-stimulating Excretion Agents Revenue (2021-2032) & (US$ Million) Figure 63. Europe Urate-stimulating Excretion Agents Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Asia-Pacific Urate-stimulating Excretion Agents Revenue (2021-2032) & (US$ Million) Figure 65. Asia-Pacific Urate-stimulating Excretion Agents Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. South America, Middle East and Africa Urate-stimulating Excretion Agents Revenue (2021-2032) & (US$ Million) Figure 67. South America, Middle East and Africa Urate-stimulating Excretion Agents Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. Urate-stimulating Excretion Agents Value Chain Figure 69. Manufacturing Cost Structure Figure 70. Urate-stimulating Excretion Agents Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Benzbromarone
  • Probenecid
  • Dotinurad
  • Lesinurad
  • Other
Applications
  • Retail Pharmacies
  • Hospitals and Clinics
  • Other
Companies covered
  • Eisai
  • Teva
  • Towa Pharmaceutical
  • Lannett Company
  • Fuji Yakuhin
  • Excella
  • AstraZeneca

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Urate-stimulating Excretion Agents Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Urate-stimulating Excretion Agents Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Urate-stimulating Excretion Agents Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Urate-stimulating Excretion Agents Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Urate-stimulating Excretion Agents Market Dynamics
  1. 2.1 Urate-stimulating Excretion Agents Industry Trends
  2. 2.2 Urate-stimulating Excretion Agents Industry Drivers
  3. 2.3 Urate-stimulating Excretion Agents Industry Opportunities and Challenges
  4. 2.4 Urate-stimulating Excretion Agents Industry Restraints
3 Urate-stimulating Excretion Agents Market by Manufacturers
  1. 3.1 Global Urate-stimulating Excretion Agents Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Urate-stimulating Excretion Agents Sales by Manufacturers (2021-2026)
  3. 3.3 Global Urate-stimulating Excretion Agents Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Urate-stimulating Excretion Agents Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Urate-stimulating Excretion Agents Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Urate-stimulating Excretion Agents Manufacturers, Product Type & Application
  7. 3.7 Global Urate-stimulating Excretion Agents Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Urate-stimulating Excretion Agents Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Urate-stimulating Excretion Agents Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Urate-stimulating Excretion Agents Tier 1, Tier 2, and Tier 3
4 Urate-stimulating Excretion Agents Market by Type
  1. 4.1 Urate-stimulating Excretion Agents Type Introduction
  2. 4.1.1 Benzbromarone
  3. 4.1.2 Probenecid
  4. 4.1.3 Dotinurad
  5. 4.1.4 Lesinurad
  6. 4.1.5 Other
  7. 4.2 Global Urate-stimulating Excretion Agents Sales by Type
  8. 4.2.1 Global Urate-stimulating Excretion Agents Sales by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Urate-stimulating Excretion Agents Sales by Type (2021-2032)
  10. 4.2.3 Global Urate-stimulating Excretion Agents Sales Market Share by Type (2021-2032)
  11. 4.3 Global Urate-stimulating Excretion Agents Revenue by Type
  12. 4.3.1 Global Urate-stimulating Excretion Agents Revenue by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Urate-stimulating Excretion Agents Revenue by Type (2021-2032)
  14. 4.3.3 Global Urate-stimulating Excretion Agents Revenue Market Share by Type (2021-2032)
5 Urate-stimulating Excretion Agents Market by Application
  1. 5.1 Urate-stimulating Excretion Agents Application Introduction
  2. 5.1.1 Retail Pharmacies
  3. 5.1.2 Hospitals and Clinics
  4. 5.1.3 Other
  5. 5.2 Global Urate-stimulating Excretion Agents Sales by Application
  6. 5.2.1 Global Urate-stimulating Excretion Agents Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Urate-stimulating Excretion Agents Sales by Application (2021-2032)
  8. 5.2.3 Global Urate-stimulating Excretion Agents Sales Market Share by Application (2021-2032)
  9. 5.3 Global Urate-stimulating Excretion Agents Revenue by Application
  10. 5.3.1 Global Urate-stimulating Excretion Agents Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Urate-stimulating Excretion Agents Revenue by Application (2021-2032)
  12. 5.3.3 Global Urate-stimulating Excretion Agents Revenue Market Share by Application (2021-2032)
6 Global Urate-stimulating Excretion Agents Sales by Region
  1. 6.1 Global Urate-stimulating Excretion Agents Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Urate-stimulating Excretion Agents Sales by Region (2021-2032)
  3. 6.2.1 Global Urate-stimulating Excretion Agents Sales by Region (2021-2026)
  4. 6.2.2 Global Urate-stimulating Excretion Agents Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Urate-stimulating Excretion Agents Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Urate-stimulating Excretion Agents Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Urate-stimulating Excretion Agents Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Urate-stimulating Excretion Agents Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Urate-stimulating Excretion Agents Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Urate-stimulating Excretion Agents Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Urate-stimulating Excretion Agents Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Urate-stimulating Excretion Agents Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Urate-stimulating Excretion Agents Revenue by Region
  1. 7.1 Global Urate-stimulating Excretion Agents Revenue by Region
  2. 7.1.1 Global Urate-stimulating Excretion Agents Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Urate-stimulating Excretion Agents Revenue by Region (2021-2026)
  4. 7.1.3 Global Urate-stimulating Excretion Agents Revenue by Region (2027-2032)
  5. 7.1.4 Global Urate-stimulating Excretion Agents Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Urate-stimulating Excretion Agents Revenue (2021-2032)
  8. 7.2.2 North America Urate-stimulating Excretion Agents Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Urate-stimulating Excretion Agents Revenue (2021-2032)
  11. 7.3.2 Europe Urate-stimulating Excretion Agents Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Urate-stimulating Excretion Agents Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Urate-stimulating Excretion Agents Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Urate-stimulating Excretion Agents Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Urate-stimulating Excretion Agents Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Eisai
  2. 8.1.1 Eisai Company Information
  3. 8.1.2 Eisai Business Overview
  4. 8.1.3 Eisai Urate-stimulating Excretion Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Eisai Urate-stimulating Excretion Agents Product Portfolio
  6. 8.1.5 Eisai Recent Developments
  7. 8.2 Teva
  8. 8.2.1 Teva Company Information
  9. 8.2.2 Teva Business Overview
  10. 8.2.3 Teva Urate-stimulating Excretion Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Teva Urate-stimulating Excretion Agents Product Portfolio
  12. 8.2.5 Teva Recent Developments
  13. 8.3 Towa Pharmaceutical
  14. 8.3.1 Towa Pharmaceutical Company Information
  15. 8.3.2 Towa Pharmaceutical Business Overview
  16. 8.3.3 Towa Pharmaceutical Urate-stimulating Excretion Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Towa Pharmaceutical Urate-stimulating Excretion Agents Product Portfolio
  18. 8.3.5 Towa Pharmaceutical Recent Developments
  19. 8.4 Lannett Company
  20. 8.4.1 Lannett Company Company Information
  21. 8.4.2 Lannett Company Business Overview
  22. 8.4.3 Lannett Company Urate-stimulating Excretion Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Lannett Company Urate-stimulating Excretion Agents Product Portfolio
  24. 8.4.5 Lannett Company Recent Developments
  25. 8.5 Fuji Yakuhin
  26. 8.5.1 Fuji Yakuhin Company Information
  27. 8.5.2 Fuji Yakuhin Business Overview
  28. 8.5.3 Fuji Yakuhin Urate-stimulating Excretion Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Fuji Yakuhin Urate-stimulating Excretion Agents Product Portfolio
  30. 8.5.5 Fuji Yakuhin Recent Developments
  31. 8.6 Excella
  32. 8.6.1 Excella Company Information
  33. 8.6.2 Excella Business Overview
  34. 8.6.3 Excella Urate-stimulating Excretion Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Excella Urate-stimulating Excretion Agents Product Portfolio
  36. 8.6.5 Excella Recent Developments
  37. 8.7 AstraZeneca
  38. 8.7.1 AstraZeneca Company Information
  39. 8.7.2 AstraZeneca Business Overview
  40. 8.7.3 AstraZeneca Urate-stimulating Excretion Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 AstraZeneca Urate-stimulating Excretion Agents Product Portfolio
  42. 8.7.5 AstraZeneca Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Urate-stimulating Excretion Agents Value Chain Analysis
  2. 9.1.1 Urate-stimulating Excretion Agents Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Urate-stimulating Excretion Agents Production Mode & Process
  6. 9.2 Urate-stimulating Excretion Agents Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Urate-stimulating Excretion Agents Distributors
  9. 9.2.3 Urate-stimulating Excretion Agents Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst